|Bid||23.96 x 800|
|Ask||24.13 x 1300|
|Day's range||22.80 - 24.20|
|52-week range||13.60 - 74.97|
|Beta (5Y monthly)||0.63|
|PE ratio (TTM)||N/A|
|Earnings date||22 Feb 2023 - 27 Feb 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||68.40|
SpringWorks' (SWTX) phase III study evaluating its investigational candidate, nirogacestat, in adult patients with progressing desmoid tumors, meets primary and key secondary endpoints.
With no product revenues due to the lack of marketed drugs, Allogene (ALLO) focuses on developing its pipeline candidates that mainly consist of allogenic CAR T therapies.
SpringWorks Therapeutics (SWTX) collaborates with AbbVie (ABBV) to evaluate the combination of nirogacestat with AbbVie's ABBV-383 for relapsed or refractory multiple myeloma.